8-K: Geron Corporation Reports First Quarter 2024 Financial Results and Provides Business Update

Geron Corporation announced its first quarter 2024 financial results, highlighted by increased revenue and a net loss, while also updating on the progress of its key clinical trials and commercial preparations.

Summary

• Geron Corporation reported a net loss of $55.4 million, or $0.09 per share, for the first quarter of 2024, compared to a net loss of $38.1 million, or $0.07 per share, for the same period in 2023.
• Revenues for the first quarter of 2024 were $304,000, a significant increase from $21,000 in the first quarter of 2023, primarily from royalties on divested stem cell assets.
• Total operating expenses for the first quarter of 2024 were $56.4 million, up from $40.1 million in the same period of 2023, driven by increased research and development and general and administrative costs.
• Research and development expenses increased to $29.4 million, compared to $27.2 million in the first quarter of 2023, due to higher manufacturing costs and personnel expenses.
• General and administrative expenses rose to $27.1 million, compared to $12.9 million in the first quarter of 2023, due to commercial preparatory activities and increased headcount.
• The company had approximately $465 million in cash and marketable securities as of March 31, 2024, including $141 million from a recent public offering.
• Geron expects total operating expenses for fiscal year 2024 to be between $270 million and $280 million.
• The company anticipates its current resources will fund operations into the second quarter of 2026.
• The PDUFA date for imetelstat's NDA for transfusion-dependent anemia in lower-risk MDS is June 16, 2024.
• The interim analysis for the IMpactMF trial is now expected in early 2026, and the final analysis in early 2027, due to lower than anticipated enrollment and death rates.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive developments like increased revenue and commercial preparations, but also negative aspects such as increased net loss and trial delays. The sentiment is neutral to slightly negative due to the increased losses and trial delays.

Positives

• Geron's revenue increased significantly year-over-year, primarily due to royalties.
• The company successfully raised $141 million through a public offering, bolstering its cash position.
• Geron has completed onboarding its commercial team, indicating readiness for a potential product launch.
• The FDA's ODAC voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat.
• The company's cash runway extends into the second quarter of 2026, providing financial stability.

Negatives

• Geron's net loss increased to $55.4 million in the first quarter of 2024, compared to $38.1 million in the same period last year.
• Operating expenses increased significantly due to commercial preparations and increased headcount.
• The timelines for the IMpactMF trial have been extended by half a year, delaying potential results.
• The company has $80 million in principal debt outstanding, leading to interest expenses.

Risks

• The approval of imetelstat by the FDA and EMA is not guaranteed, and the PDUFA date of June 16, 2024, is a key milestone.
• The company may need to raise additional capital to fund the development and commercialization of imetelstat.
• Delays in manufacturing or supplying imetelstat could impact the commercial launch and clinical trials.
• The actual enrollment and death rates in the IMpactMF trial could further impact the timing of the interim and final analyses.
• There are risks associated with the commercial launch of imetelstat, including market acceptance and reimbursement.

Future Outlook

Geron anticipates its current resources will fund operations into the second quarter of 2026, based on current operating plans and assumptions regarding the potential approval and commercial launch of imetelstat. The company also plans to grow to 250-300 employees by year-end 2024, subject to imetelstat approval.

Management Comments

• John A. Scarlett, M.D., Chairman and Chief Executive Officer, stated that they have continued working with the FDA as they complete their review of the New Drug Application for imetelstat, which has a June 16, 2024 PDUFA target action date.
• Management is actively preparing for a successful launch of imetelstat in the U.S., if approved, including onboarding the sales force and refining market research.

Industry Context

Geron is a late-stage clinical biopharmaceutical company focused on developing therapies for hematologic malignancies. The company's lead product, imetelstat, is a first-in-class telomerase inhibitor. The announcement comes as the company is preparing for a potential commercial launch of imetelstat, which would position them as a key player in the treatment of transfusion-dependent anemia in lower-risk MDS.

Comparison to Industry Standards

• Geron's increased operating expenses are typical for a company transitioning from clinical to commercial stage, similar to other biopharmaceutical companies preparing for product launches.
• The company's cash runway into Q2 2026 is a positive sign, comparable to other companies with similar development timelines.
• The delay in the IMpactMF trial is not uncommon in clinical trials, and the company's transparency in updating timelines is consistent with industry best practices.
• Companies like Karyopharm Therapeutics and Agios Pharmaceuticals, which also focus on hematologic malignancies, have faced similar challenges in clinical development and commercialization.
• The increase in revenue from royalties is a positive sign, but the overall net loss is a concern, similar to other companies in the development stage.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the delay in the IMpactMF trial.
• Employees may be impacted by the planned increase in headcount as the company transitions to a commercial stage.
• Patients with transfusion-dependent anemia in lower-risk MDS are awaiting the potential approval of imetelstat.
• Creditors may be monitoring the company's financial performance and debt levels.

Next Steps

• Geron will continue working with the FDA on the review of the imetelstat NDA.
• The company will continue preparations for a potential U.S. commercial launch of imetelstat.
• Geron will continue to enroll patients in the IMpactMF trial.
• The company will monitor the progress of the IMpactMF trial and provide updates on the interim and final analyses.
• Geron will continue to support the ongoing clinical trials IMpactMF, IMproveMF and IMpress, as well as the long-term treatment and follow-up of remaining patients in IMerge.

Key Dates

Keywords

imetelstat, myelodysplastic syndromes, MDS, myelofibrosis, hematologic malignancies, clinical trial, PDUFA, FDA, commercial launch, financial results